4838-96-4

Basic information

• Product Name: Benzenethanamine, 3,4,5-trimethoxy-N-methyl-
• Synonyms: Benzenethanamine, 3,4,5-trimethoxy-N-methyl-;N-Methylmescaline
• CAS NO: 4838-96-4
• Molecular Formula: C₁₂H₁₉NO₃
• Molecular Weight: 225
• Mol File: 4838-96-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 201-202 °C
• Boiling Point: 315.5°Cat760mmHg
• Flash Point: 131.3°C
• Appearance: /
• Density: 1.025g/cm³
• Vapor Pressure: 0.000437mmHg at 25°C
• Refractive Index: 1.495
• PKA: 10.05±0.10(Predicted)
• CAS DataBase Reference: Benzenethanamine, 3,4,5-trimethoxy-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenethanamine, 3,4,5-trimethoxy-N-methyl-(4838-96-4)
• EPA Substance Registry System: Benzenethanamine, 3,4,5-trimethoxy-N-methyl-(4838-96-4)

Safety Data

• Hazardous Substances Data: 4838-96-4(Hazardous Substances Data)

Usage

Description

Benzenethanamine, 3,4,5-trimethoxy-N-methyl-, also known as Anhalonium Lewinii Hennings, is a liquid alkaloid derived from the plant of the same name. It is characterized by its ability to form a crystalline picrate with a melting point of 177.5-178.5°C. The chemical structure of this compound has been confirmed through synthesis.

Uses

1. Used in Pharmaceutical Industry:
Benzenethanamine, 3,4,5-trimethoxy-N-methylis used as an active pharmaceutical ingredient for its potential therapeutic effects. Benzenethanamine, 3,4,5-trimethoxy-N-methyl-'s unique structure and properties make it a promising candidate for the development of new drugs and treatments.
2. Used in Chemical Synthesis:
This alkaloid is also used as a starting material or intermediate in the synthesis of various organic compounds. Its reactivity and structural features allow for the creation of a wide range of chemical products, contributing to the advancement of organic chemistry.
3. Used in Research and Development:
Benzenethanamine, 3,4,5-trimethoxy-N-methylis utilized in research laboratories for studying its chemical properties, potential applications, and interactions with other compounds. This helps in understanding its role in various biological processes and identifying new areas of application.
4. Used in Quality Control and Analysis:
Benzenethanamine, 3,4,5-trimethoxy-N-methylis employed in quality control processes to ensure the purity and authenticity of pharmaceutical products containing it. Analytical techniques such as chromatography and spectroscopy are used to determine the presence and concentration of Benzenethanamine, 3,4,5-trimethoxy-N-methylin various formulations.

References

Spath, Becke., Monatsh., 66,327 (1935) Spath, Becke., Ber., 68,501,944 (1935)

InChI:InChI=1/C12H19NO3/c1-13-6-5-9-7-10(14-2)12(16-4)11(8-9)15-3/h7-8,13H,5-6H2,1-4H3

Upstream product

• 54-04-6 mescaline 
• 54767-81-6 5-(epoxyethyl)-1,2,3-tris(methoxy)benzene 
• 5320-31-0 3,4,5-trimethoxyphenylacetaldehyde 
• 74-89-5 methylamine 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 134-96-3 syringic aldehyde 
• 39053-78-6 3,4,5-trimethoxyphenylacetyl chloride 
• 951-82-6 3,4,5-trimethoxyphenyl acetic acid 
• 101752-05-0 methanol hydrochloride 
• 7702-09-2 2-diazo-1-(3,4,5-trimethoxyphenyl)ethanone 
• 873381-36-3 benzylidene-(3,4,5-trimethoxy-phenethyl)-amine 
• 74-88-4 methyl iodide 

Downstream Products

• 96255-20-8 1[7,8-Dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-methyl-N-(2-{3,4,5-trimethoxy-phenyl}-ethyl)-amino]-propane hydrochloride 
• 637774-00-6 (E)-N-methyl-3-(3-pyridyl)-N-(3,4,5-trimethoxyphenethyl)-2-propenoic acid amide 
• 1028089-99-7 2-{methyl[2-(3,4,5-trimethoxyphenyl)ethyl]amino}benzaldehyde 
• 1277187-95-7 1-(3-benzyloxybenzyl)-2-methyl-6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1277187-96-8 1-(3-hydroxybenzyl)-2-methyl-6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1316259-15-0 (R)-1-(3-hydroxybenzyl)-2-methyl-6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1277187-94-6 2-(3-benzyloxyphenyl)-N-methyl-N-(3,4,5-trimethoxyphenethyl)acetamide 
• 1316259-14-9 (S)-9-hydroxy-1,2,3-trimethoxyberbine 
• 133675-42-0 2-isopropyl-1-[4-{3-[N-methyl-N-(3,4,5-trimethoxy-β-phenethyl)amino]propyloxy}benzenesulphonyl]indolizine 
• 112946-90-4 (-)-SA₂₅₇₂ 
• 116311-93-4 (+)-SA₂₅₇₂ 
• 127732-35-8 2-[5-Methoxy-2-(4-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-butoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one 
• 127732-33-6 2-[5-Methoxy-2-(3-{methyl-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-amino}-propoxy)-phenyl]-4-methyl-4H-benzo[1,4]thiazin-3-one 
• 6308-78-7 trimethyl-(3,4,5-trimethoxy-phenethyl)-ammonium; iodide 

Relevant articles and documents

Solvolysis, Electrochemistry, and Development of Synthetic Building Blocks from Sawdust

Either aldehyde or cinnamyl ether products can be selectively extracted from raw sawdust by controlling the temperature and pressure of a solvolysis reaction. These materials have been used as platform chemicals for the synthesis of 15 different synthetic substrates. The conversion of the initial sawdust-derived materials into electron-rich aryl substrates often requires the use of oxidation and reduction chemistry, and the role electrochemistry can play as a sustainable method for these transformations has been defined.

Biocatalytic organic synthesis of optically pure (S)-scoulerine and berbine and benzylisoquinoline alkaloids

A chemoenzymatic approach for the asymmetric total synthesis of the title compounds is described that employs an enantioselective oxidative C-C bond formation catalyzed by berberine bridge enzyme (BBE) in the asymmetric key step. This unique reaction yielded enantiomerically pure (R)-benzylisoquinoline derivatives and (S)-berbines such as the natural product (S)-scoulerine, a sedative and muscle relaxing agent. The racemic substrates rac-1 required for the biotransformation were prepared in 4-8 linear steps using either a Bischler-Napieralski cyclization or a C1-Cα alkylation approach. The chemoenzymatic synthesis was applied to the preparation of fourteen enantiomerically pure alkaloids, including the natural products (S)-scoulerine and (R)-reticuline, and gave overall yields of up to 20% over 5-9 linear steps.

Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives

The present invention relates to an agent for treating nephritis and a TGF-β inhibiting agent comprising as an effective ingredient a pyridylacrylamide derivative represented by the following formula (I): wherein Ar1is a substituted or unsubstituted pyridyl group, Ar2is a substituted or unsubstituted phenyl group, R1is a hydrogen atom, an alkyl group or an aryl group, R2is a hydrogen atom, an alkyl group, a cyano group or an alkoxycarbonyl group, R3is a hydrogen atom or an optionally substituted alkyl group, X is an oxygen or sulfur atom, A and B are same or different and each represent a hydrogen atom, a hydroxyl group, an alkoxy group or an alkylthio group, or A and B together form an oxo or thioxo group, or a group represented by the formula: ═N—Y in which Y is a dialkylamino, hydroxyl, aralkyloxy or alkoxy group, or a group represented by the formula: —Z1—M—Z2— which Z1and Z2are same or different and each represent an oxygen or sulfur atom or an imino group optionally substituted by an alkyl group, and M is an alkylene group or a 1,2-phenylene group, or A is a hydroxyl group and B is a 1-alkylimidazol-2-yl group, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof; as well as the pyridylacrylamide derivatives.